Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Tardive dyskinesia Indication Strategy Report 2026: VMAT2, Trials and Deals
21 July 2026
Tardive dyskinesia indication strategy report covering epidemiology, VMAT2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Tourette syndrome Indication Strategy Report 2026: D2 receptor, Trials and Deals
21 July 2026
Tourette syndrome indication strategy report covering epidemiology, D2 receptor biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Idiopathic hypersomnia Indication Strategy Report 2026: GABRA1, Trials and Deals
21 July 2026
Idiopathic hypersomnia indication strategy report covering epidemiology, GABRA1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Tay-Sachs disease Indication Strategy Report 2026: HEXA, Trials and Deals
21 July 2026
Tay-Sachs disease indication strategy report covering epidemiology, HEXA biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
GM1 gangliosidosis Indication Strategy Report 2026: β-galactosidase, Trials and Deals
21 July 2026
GM1 gangliosidosis indication strategy report covering epidemiology, β-galactosidase biology, active trials, competition and deal signals using PatSnap MCP evidence.
8 min read
DENND5B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND5B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DENND5A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND5A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DENND4C Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND4C, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DENND4B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND4B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DENND4A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND4A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DENND2D Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DENND2D, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Batten disease Indication Strategy Report 2026: CLN3, Trials and Deals
21 July 2026
Batten disease indication strategy report covering epidemiology, CLN3 biology, active trials, competition and deal signals using PatSnap MCP evidence.